Skip to main content

Advertisement

SpringerLink
Log in

Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature

  • Special Feature
  • Current topics in endocrine therapy for breast cancer
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

The selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene exert their estrogen agonist and antagonist actions depending on the target organ and individual circumstances. For instance, tamoxifen increases bone mineral density in postmenopausal patients, but decreases it in premenopausal patients when it is used as the adjuvant therapy for breast cancer in both populations. Due to positive results from recent large clinical trials for early breast cancer, the aromatase inhibitors (AIs) are the agent of first choice for postmenopausal patients. However, the veteran SERM tamoxifen is still the primary drug for premenopausal breast cancer patients, patients with ductal carcinoma in situ and subset of postmenopausal women. Recent accumulated data suggest that both raloxifene and tamoxifen could be useful in chemoprevention. Further investigation should be made into the development of a systematic strategy for application to a suitable target population, i.e., one more likely to develop hormone receptor-positive breast cancer. Unlike the AIs, SERMs have a distinct function that does not directly relate to hormone receptors when used in higher pharmacological concentration. The attempt to overcome chemo-drug resistance using high-dose SERMs would be one approach to developing such a strategy. There were several reports showing the antiproliferative effect of SERMs for estrogen receptor-negative cells, such as glioma. There are still numerous possible applications for SERMs when their intrinsic nature is utilized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jordan VC, O’Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol. 2007;25(36):5815–24.

    Article  PubMed  CAS  Google Scholar 

  2. Hasmann M, Rattel B, Loser R. Preclinical data for droloxifene. Cancer Lett. 1994;84(2):101–16.

    Article  PubMed  CAS  Google Scholar 

  3. Johnston SR, Boeddinghaus IM, Riddler S, Haynes BP, Hardcastle IR, Rowlands M, et al. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res. 1999;59(15):3646–51.

    PubMed  CAS  Google Scholar 

  4. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol. 2007;25(31):4967–73.

    Article  PubMed  CAS  Google Scholar 

  5. Arpino G, Nair Krishnan M, Doval Dinesh C, Bardou VJ, Clark GM, Elledge RM. Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. Ann Oncol. 2003;14(2):233–41.

    Article  PubMed  CAS  Google Scholar 

  6. Buzdar A, Hayes D, El-Khoudary A, Yan S, Lonning P, Lichinitser M, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002;73(2):161–75.

    Article  PubMed  CAS  Google Scholar 

  7. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717.

    Google Scholar 

  8. Belfiglio M, Valentini M, Pellegrini F, De Berardis G, Franciosi M, Rossi MC, et al. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). Cancer. 2005;104(11):2334–9.

    Article  PubMed  CAS  Google Scholar 

  9. Swedish Breast Cancer Cooperative Group (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.. J Natl Cancer Inst 88(21):1543–9.

    Google Scholar 

  10. Delozier T, Spielmann M, Mace-Lesec’h J, Janvier M, Hill C, Asselain B, et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol. 2000;18(20):3507–12.

    PubMed  CAS  Google Scholar 

  11. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001;93(6):456–62.

    Article  PubMed  CAS  Google Scholar 

  12. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93(9):684–90.

    Article  PubMed  CAS  Google Scholar 

  13. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst. 1996;88(24):1828–33.

    Article  PubMed  CAS  Google Scholar 

  14. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262–71.

    PubMed  CAS  Google Scholar 

  15. Peto R. ATLAS (2007) (Adjuvant tamoxifen-longer against shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women-preliminary results. San Antonio Breast Cancer Symposium vol 30, #48.

  16. NCCN (2008) NCCN clinical practice guidelines in oncology, breast cancer. http://www.nccn.org V.2.

  17. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.

    Article  PubMed  CAS  Google Scholar 

  18. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102.

    Article  PubMed  Google Scholar 

  19. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.

    PubMed  CAS  Google Scholar 

  20. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817–24.

    Article  PubMed  CAS  Google Scholar 

  21. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272–82.

    Article  PubMed  CAS  Google Scholar 

  22. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283–90.

    Article  PubMed  CAS  Google Scholar 

  23. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst. 2007;99(9):727–37.

    Article  PubMed  CAS  Google Scholar 

  24. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial multiple. Outcomes of raloxifene evaluation. JAMA. 1999;281(23):2189–97.

    Article  PubMed  CAS  Google Scholar 

  25. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751–61.

    PubMed  CAS  Google Scholar 

  26. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37.

    Article  PubMed  CAS  Google Scholar 

  27. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.

    Article  PubMed  CAS  Google Scholar 

  28. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst. 2007;99(5):350–6.

    Article  PubMed  CAS  Google Scholar 

  29. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 1997;277(5331):1508–10.

    Article  PubMed  CAS  Google Scholar 

  30. van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514–27.

    Article  PubMed  Google Scholar 

  31. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558–68.

    PubMed  CAS  Google Scholar 

  32. Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer. 2006;119(7):1683–9.

    Article  PubMed  CAS  Google Scholar 

  33. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001;19(1):18–27.

    PubMed  CAS  Google Scholar 

  34. Saji S, Ishizuka N, Horiguchi K, Suzuki E, Bando H, Aruga T, Takahashi I, Tominaga T, Toi M (2006) Age frequency distribution of joint ER/PR phenotypes in primary breast cancer patients: an analysis of 3620 cases at a single Japanese institute. Proc Am Soc Clin Oncol 597.

  35. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97(17):1254–61.

    Article  PubMed  CAS  Google Scholar 

  36. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829–46.

    Article  PubMed  CAS  Google Scholar 

  37. ACOG (2006) Tamoxifen and endometrial cancer. American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 336. ACOG (2006).

  38. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14(1):78–84.

    PubMed  CAS  Google Scholar 

  39. Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92(11):903–11.

    Article  PubMed  CAS  Google Scholar 

  40. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19(2):343–53.

    PubMed  CAS  Google Scholar 

  41. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–2.

    Article  PubMed  CAS  Google Scholar 

  42. Goss P, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH Jr, Langecker P, et al. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol. 2007;25(31):4961–6.

    Article  PubMed  CAS  Google Scholar 

  43. Maruyama S, Kuroiwa S, Shibasakai C, Ekimoto H, Nomura Y. Hormonal effects and in vitro antitumor effect of toremifene (NK622), a new antiestrogenic drug, and its metabolites. J Jpn Soc Cancer Ther. 1993;28(5):811–8.

    CAS  Google Scholar 

  44. Kang Y, Cortina R, Perry RR. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. J Natl Cancer Inst. 1996;88(5):279–84.

    Article  PubMed  CAS  Google Scholar 

  45. Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, et al. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004;64(24):9115–23.

    Article  PubMed  CAS  Google Scholar 

  46. Pu YS, Hsieh TS, Tsai TC, Cheng AL, Hsieh CY, Su IJ, et al (1995) Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol 154 (2 Pt 1):601–5.

    Google Scholar 

  47. Desai PB, Bhardwaj R, Damle B. Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells. Cancer Chemother Pharmacol. 1995;36(5):368–72.

    Article  PubMed  CAS  Google Scholar 

  48. Rao US, Fine RL, Scarborough GA. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994;48(2):287–92.

    Article  PubMed  CAS  Google Scholar 

  49. Mubashar M, Harrington KJ, Chaudhary KS, Lalani el N, Stamp GW, Sinnett D et al (2002) 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med 43(4):519–25.

    Google Scholar 

  50. Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci. 2006;97(11):1198–1204.

    Article  PubMed  CAS  Google Scholar 

  51. Cheng AL, Chuang SE, Fine RL, Yeh KH, Liao CM, Lay JD, et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol. 1998;55(4):523–31.

    Article  PubMed  CAS  Google Scholar 

  52. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem. 1997;272(3):1682–87.

    Article  PubMed  CAS  Google Scholar 

  53. Tominaga T, Hayashi K, Hayasaka A, Asaishi K, Abe R, Kimishima I, et al. Phase I study of NK 622 (toremifene citrate). Gan To Kagaku Ryoho. 1992;19(14):2363–72.

    PubMed  CAS  Google Scholar 

  54. Wurz GT, Emshoff VD, DeGregorio MW, Wiebe VJ. Targeting chemosensitizing doses of toremifene based on protein binding. Cancer Chemother Pharmacol. 1993;31(5):412–4.

    Article  PubMed  CAS  Google Scholar 

  55. Tominaga T, Abe O, Izuo M, Nomura Y. Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study. Gan To Kagaku Ryoho. 1993;20(1):79–90.

    PubMed  CAS  Google Scholar 

  56. Stuart NS, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, et al. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer. 1992;66(5):833–9.

    PubMed  CAS  Google Scholar 

  57. Berman E, McBride M, Tong W. Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines. Leukemia. 1994;8(7):1191–6.

    PubMed  CAS  Google Scholar 

  58. Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmen J, Anttila M, et al. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol. 2000;46(1):27–34.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was supported by the grant from the Tokyo Metropolitan Government Bureau of Public Health and the Ministry of Health, Labour, and Welfare of Japan.

Author information

Authors and Affiliations

  1. Division of Clinical Trials and Research, Department of Breast Surgery and Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan

    Shigehira Saji & Katsumasa Kuroi

Authors
  1. Shigehira Saji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsumasa Kuroi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigehira Saji.

About this article

Cite this article

Saji, S., Kuroi, K. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature. Breast Cancer 15, 262–269 (2008). https://doi.org/10.1007/s12282-008-0063-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-008-0063-y

Keywords

Search

Navigation